|
AU2019272184A1
|
|
Antigen variant of varicella zoster virus and use thereof
|
|
WO2019124973A1
|
|
Protein conjugate and fusion protein which comprise albumin and lysosomal enzyme
|
|
SG11202004529XA
|
|
Transformed human cell and use thereof
|
|
KR20200047937A
|
|
Fusion protein comprising ids and use thereof
|
|
CA3076972A1
|
|
Anti-bcma antibody having high affinity for bcma and pharmaceutical composition for treatment of cancer, comprising same
|
|
KR20190137294A
|
|
Antibody library and Screening Method of Antibody by Using the Same
|
|
KR20190117681A
|
|
Bispecific Antibodies That Bind HER3 and CD3
|
|
CN110475788A
|
|
Anti- CEACAM1 antibody and its application
|
|
KR20190086269A
|
|
Long-acting recombinant glycoproteins and menufacturing method thereof
|
|
WO2018124615A1
|
|
Herpes zoster vaccine composition
|
|
US2019365884A1
|
|
Varicella zoster virus vaccine
|
|
WO2018097642A1
|
|
Varicella zoster virus vaccine
|
|
EP3476937A1
|
|
Chimera protein comprising fviii and vwf factors, and use thereof
|
|
CN109689683A
|
|
Recombinant single chain FV III and its chemically conjugated object
|
|
US2019135884A1
|
|
Composition comprising an ab6 family designer ligand of tgf-beta superfamily for treating bone and cartilage disease and use thereof
|
|
WO2017209522A1
|
|
Composition comprising an ab6 family designer ligand of tgf-beta superfamily for treating liver disease and use thereof
|
|
US2020325216A1
|
|
Ab6 family designer ligands of tgf-beta superfamily
|
|
KR20180120893A
|
|
Fusion protein comprising pvr and 4-1bbl, and use thereof
|
|
KR20180071651A
|
|
Transgenic mouse expressing inactivated human iduronate-2-sulphatase and method for improving a hunter syndrome treating agent using same
|
|
KR20180060062A
|
|
Novel Antibody Against AXL and Pharmaceutical Composition Comprising the Same
|
